Literature DB >> 9802362

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper.

J Bousquet1, R Lockey, H J Malling.   

Abstract

The World Health Organization and various allergy, asthma, and immunology societies throughout the world met on January 27 through 29, 1997, in Geneva, Switzerland to write guidelines for allergen immunotherapy. Over the ensuing year, the editors and panel members reached a consensus about the information to include in the WHO position paper "Allergen immunotherapy: Therapeutic vaccines for allergic diseases." The historical term allergen extract was changed to allergen vaccine to reflect the fact that allergen vaccines are used in medicine as immune modifiers. The document summarizes the scientific literature and rationale for the appropriate use of such therapy to treat allergic rhinoconjunctivitis, allergic asthma, and Hymenoptera hypersensitivity. It also includes recommendations to improve safety, discusses new techniques being developed that may result in better efficacy and less risk, and offers recommendations for areas of additional and necessary research.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802362     DOI: 10.1016/s0091-6749(98)70271-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  200 in total

1.  How now, brown cow, vaccine or extract?

Authors:  Richard F Lockey
Journal:  Curr Allergy Asthma Rep       Date:  2002-05       Impact factor: 4.806

Review 2.  The potential of peptide immunotherapy in allergy and asthma.

Authors:  F Runa Ali; A Barry Kay; Mark Larché
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

3.  Electrophoretic investigations of the acid conformational change of alpha-lactalbumin.

Authors:  K Kuwajima; K Nitta; S Sugai
Journal:  J Biochem       Date:  1975-07       Impact factor: 3.387

4.  Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.

Authors:  C Barth; F Anero; O Pfaar; L Klimek; K Hörmann; B A Stuck
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-09       Impact factor: 2.503

5.  Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.

Authors:  Hans Grönlund; Susanne Vrtala; Ursula Wiedermann; Gerhard Dekan; Dietrich Kraft; Rudolf Valenta; Marianne Van Hage-Hamsten
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

6.  Treatment of seasonal allergic rhinitis: useless versus helpful allergy therapy.

Authors:  Michael L Loren
Journal:  BMJ       Date:  2003-11-22

Review 7.  Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence?

Authors:  Sarah K Wise; Rodney J Schlosser
Journal:  Am J Rhinol Allergy       Date:  2012 Jan-Feb       Impact factor: 2.467

Review 8.  Fatalities following allergen immunotherapy.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 9.  Adjuvants for allergy vaccines.

Authors:  Philippe Moingeon
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 10.  Allergen immunotherapy for allergic respiratory diseases.

Authors:  Antonio Cappella; Stephen R Durham
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.